July 13, 2021 7:59am
Inflation data is expected today and to climb
News: Ionis Pharmaceuticals, Inc. (IONS) has entered into an exclusive licensing agreement with Bicycle Therapeutics plc (BCYC) to improve delivery of antisense medicines to muscle tissue, including cardiac muscle, as well as the potential to cross the blood brain barrier
The Biostage (BSTG) Chronicles: Yet another accounting firm, is this the third? <read more>
Pre-open indications: BUY: BLUE, EDIT; SELL: ALNY, GBT; 1 Maintain SELL: BSTG
My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session
Dow futures are DOWN -0.11% (-37 points), S&P futures are UP +0.02% (+1 point) and NASDAQ futures are UP +0.33% (+49 points)
Pre-open futures (Dow and S&P) were fluctuating and slippery although the Nasdaq was positive on Tuesday morning
European stocks struggled for direction
Asia-Pacific stocks were mostly higher as investors reacted to the release of China’s trade data for June which showed exports jumped 32.2% compared with a year earlier, customs data showed.
Data Docket: June’s Consumer Price Index
Henry’omics:
Earnings’ season begins today, not our sector until we get closer to the end of the month.
Monday’s evening’s recap: “feeling the squeeze of sentiment” … https://www.regmedinvestors.com/articles/11994
- The Nasdaq closed UP +31.32 points (+0.21);
- The IBB closed down -0.37% and XBI closed down -1.47%
- Sector volume was LOW with 2 of the 11-upside having higher than the 3-month average volume with NADA volume of 0 of 19-downside having higher than the 3-month average volume;
- The CBOE Volatility Index (VVIX: INDEX) was down -0.01 points or -0.06% at 16.17
- Monday’s percentage (%) of the 11-upside were +0.04% (RARE) to +11.28% (BLCM) while the 19-downside ranges from -0.64% (MESO) to -5.15% (EDIT);
Q3/21: 3 positive and 4 negative close
Q2/21:
- June: 15 positive and 8 negative closes
- May: 8 positive, 12 negative closes and 1 holiday
- April: 11 negative and 10 positive closes
Q1/21:
- March: 10 positive, 12 negative and 1 neutral closes
- February: 9 positive, 10 negative closes and 1 holiday
- January: 10 positive, 9 negative closes and 1 holiday
Companies in my headlights – It’s your decision; I provide an idea and context:
The Biostage (BSTG) Chronicles - Maintaining Sell – Could the share price stay up if it wasn’t being “pumped”?
Biostage (BSTG) closed flat again even though 2,628 shares traded Monday after Friday’s $1.50 with 1,060 shares traded after Thursday’s +$0.23 to $1.50 with 210 shares traded, Wednesday’s -$0.23 to $1.27 with 15,903 shares traded and last Tuesday’s +$0.15 to $1.50 with 5,702 shares traded.
Question#1: Has Beijing, China “spoken” as yet another accounting firm has been retained? On July 6, 2021, BSTG’s Audit Committee engaged Wei, Wei & Co., LLP (with offices in Queens, New York, Los Angeles, California, and Beijing, China) to serve as the independent registered public accounting firm contingent upon completion of Wei’s client acceptance procedures - which will probably be waived by Beijing? Licensed to practice as certified public accountants in the states of New York, Connecticut, California, and New Jersey – what about Massachusetts?
Question#2: Is this also the third (3rd) accounting firm in five (5) years?
MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.
The morning’s indications:
Maintaining BUY
bluebird bio (BLUE) closed down -$0.78 to $29.79 after Friday’s +$0.14 to $30.57 and has a positive +$0.31 or +1.04% aftermarket indication.
Editas Medicine (EDIT) closed down -$2.50 to $46.07 after Friday’s +$2.35, Thursday’s +$0.52, Wednesday’s -$2.44 and last Tuesday’s -$6.76 with a positive +$0.05 or +0.11% aftermarket indication.
Ionis Pharmaceuticals (IONS) closed down -$1.58 to $37.29 after Friday’s $38.87, Thursday’s $38.79, Wednesday’s $38.96 and last Tuesday’s $39.33 with a positive +$0.11 or +0.29% pre-market indication based on news.
Maintaining SELL:
Alnylam Pharmaceuticals (ALNY) closed up +$0.29 to $177.03 after Friday’s $176.74, Thursday’s $172.50, Wednesday’s $172.59 and last Tuesday’s -$174.38 with a negative -$0.64 or -0.36% aftermarket indication
Global Blood Therapeutics (GBT) closed down -$0.41 to $34.49 after Friday’s +$0.77 to $34.90 but, has a negative -$1.15 or -3.33% aftermarket indication.
The BOTTOM LINE: Is this a session of “any which way” works … as my vacation gets off to a slow start if any.
It takes courage to not being discouraged by “our” universe of cell and gene therapy equities or sector …
In my role as a research analyst and journalist is a balancing “act”, WHAT CHANGES; many times, I scratch my head over how to cover volatile cell and gene therapy equities – it’s the INDICATIONS that focus my “leanings”.
I also continue to MAINTAIN, this is a confused sector as sentiment rages and fades, momentum is usurped, fundamentals are being ignored.
My focus has always been “indication and warning analysis” … my advice, trim and skim any new highs if one can!” I also see a number of lows that could be in the “pick-up” stock game.
My motto, never leave an investor uninformed about what I know!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
